Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Ribociclib
by Highest Patent Value in the world in 2021

The Ribociclib top 20 is Discovery PatSnap’ annual ranking of the top 20 Highest Patent Value Ribociclib Key Players in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2021, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Health care,Clinical trial,Drug,
...[+2]
Avg patent value: 490,000
2
Basel-Stadt, Switzerland
Dosage form,Health care,Medicine,
...[+2]
Avg patent value: 397,548
3
Medicine,Prescription drug,Cardiovascular agent,
...[+2]
Avg patent value: 350,000
4
Avg patent value: 280,000
5
Avg patent value: 180,000
6
Avg patent value: 160,000
7
Shanghai Yaoda Biotechnology Co., Ltd.
Avg patent value: 110,000
8
Avg patent value: 71,000
9
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Avg patent value: 64,000
10
Noord-Brabant, Netherlands
Avg patent value: 53,000
11
Ontario, Canada
Avg patent value: 52,500
12
Avg patent value: 23,000
13
Avg patent value: 22,000
14
Tel Aviv, Israel
Gastrointestinal agent,Immunotherapy,Clinical trial,
...[+2]
Avg patent value: 17,000
15
Avg patent value: 16,000
16
Oncology,Medicine,Health care,
...[+2]
Avg patent value: 15,000
17
Contract research organization,Health care,Liposome,
...[+2]
Avg patent value: 3,600
18
Avg patent value: 3,600
19
Avg patent value: 3,500
20
Avg patent value: 3,400
Page generation time: Jul 07 2025